← Back to Search

Stem Cell Therapy

Intravitreal autologous CD34+ cells for Retinitis Pigmentosa (BMSCRP1 Trial)

Phase 1
Waitlist Available
Led By Susanna Park, MD PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

BMSCRP1 Trial Summary

This trial will test whether it is safe to give participants with retinitis pigmentosa an injection of their own stem cells in order to improve their vision.

Eligible Conditions
  • Retinitis Pigmentosa

BMSCRP1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of intravitreal injection of autologous CD34+ cells
Safety of intravitreal injection of autologous CD34+ cells
Secondary outcome measures
Best corrected visual acuity
Electroretinography
Microperimetry
+2 more

BMSCRP1 Trial Design

1Treatment groups
Experimental Treatment
Group I: Intravitreal autologous CD34+ cellsExperimental Treatment1 Intervention
Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
910 Previous Clinical Trials
4,706,987 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
453 Patients Enrolled for Retinitis Pigmentosa
Cures Within ReachOTHER
19 Previous Clinical Trials
1,739 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
12 Patients Enrolled for Retinitis Pigmentosa
Retina SocietyUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently a recruitment period for this research experiment?

"Affirmative. As documented on clinicaltrials.gov, this medical experiment is presently accepting participants - the study was first posted on June 1st 2021 and has since been updated on September 1st 2022. 4 patients are required for one location."

Answered by AI

How many subjects are currently engaged in this experiment?

"Affirmative. Data on clinicaltrials.gov reveals that this investigation is actively enrolling participants, with its initial post date being June 1st 2021 and the most recent update occurring September 1st 2022. The study aims to enlist 4 individuals from a single centre."

Answered by AI

What end goals are researchers striving to achieve with this experiment?

"The primary goal of this 6-month long study is to determine the practicality of administering autologous CD34+ cells intravitreally. Other important metrics for evaluation include Electroretinography (with an emphasis on changes in "a" and "b" wave amplitude from baseline), National Eye Institute Vision Questionnaire results, and Microperimetry scores (measuring change in reduced sensitivity)."

Answered by AI

Has the FDA sanctioned Intravitreal autologous CD34+ cells for use in treatment?

"The safety of Intravitreal autologous CD34+ cells is thought to be low, as evidenced by its rating of 1. This assessment reflects the fact that this clinical trial is in Phase 1 and there are limited data demonstrating efficacy or safety."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
Arizona
Florida
Other
How old are they?
18 - 65
What site did they apply to?
University of California Davis
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Looking for a solution for RP. I am just looking for a solution to my eye situation.
PatientReceived 1 prior treatment
My vision is declining and I would like to maintain some degree of independence before My Time.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Susanna Park, MD, PhD 2021. "Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04925687.
All > Retinitis Pigmentosa
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top